Aimmune Therapeutics Inc Quick Ratio (AIMT) starting from the second quarter 2020 to second quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aimmune Therapeutics Inc   (NASDAQ: AIMT)

Aimmune Therapeutics Inc 's Quick Ratio

AIMT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2020, Quick Ratio deteriorated to 7.73 below Aimmune Therapeutics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Quick Ratio than Aimmune Therapeutics Inc in second quarter 2020. While Quick Ratio total ranking in the second quarter 2020 has deteriorated compared to the prior quarter from 441 to 503.

Explain Quick Ratio?
How much Cash & cash equivalents AIMT´s has?
What are AIMT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AIMT Quick Ratio (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2
Y / Y Current Liabilities Change -1.43 % 19.32 % 18.89 % 10.66 % 14.12 %
Y / Y Cash & cash equivalent Change 28.84 % 26.55 % -52.78 % -23.42 % -15.98 %
Quick Ratio MRQ 7.73 8.31 3.18 4.72 5.92
AIMT's Total Ranking # 503 # 441 # 1025 # 503 # 626
Seq. Current Liabilities Change -5.8 % -4.62 % 9.05 % 0.61 % 14.02 %
Seq. Cash & cash equivalent Change -12.39 % 149.7 % -26.58 % -19.78 % -13.95 %



Quick Ratio second quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 253
Overall Market # 503


Quick Ratio Statistics
High Average Low
69.87 16.55 3.18
(Sep 30 2015)   (Dec 31 2019)




Financial Statements
Aimmune Therapeutics Inc 's Current Liabilities $ 41 Millions Visit AIMT's Balance sheet
Aimmune Therapeutics Inc 's Cash & cash equivalent $ 314 Millions Visit AIMT's Balance sheet
Source of AIMT's Sales Visit AIMT's Sales by Geography


Cumulative Aimmune Therapeutics Inc 's Quick Ratio

AIMT's Quick Ratio for the trailling 12 Months

AIMT Quick Ratio

 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth 11.5 % 15.74 % 15.48 % 20.08 % 33.67 %
Y / Y Cash & cash equivalent TTM Growth -6.88 % -16.9 % -26.07 % -13.97 % -5.54 %
Quick Ratio TTM 5.94 5.51 5.28 6.55 7.11
Total Ranking TTM # 4184 # 390 # 247 # 426 # 4115
Seq. Current Liabilities TTM Growth -0.34 % 4.26 % 4.58 % 2.61 % 3.45 %
Seq. Cash & cash equivalent TTM Growth 7.47 % 8.68 % -15.63 % -5.5 % -4.09 %

Quick ratio ranking by company, industry and sector >> Back to AIMT Financial Strength Comparisons >> Go to Compare AIMT Quick Ratio to its Competitors

On the trailing twelve months basis AIMT Cash & cash equivalent grew by 28.84 % in Q2 2020 year on year, while Current Liabilities decreased to $41 millions, this led to increase in in Aimmune Therapeutics Inc 's Quick Ratio to 5.94, Quick Ratio remained below AIMT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 457 other companies have achieved higher Quick Ratio than Aimmune Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2020 from 390 to 4184.

Explain Quick Ratio?
How much Cash & cash equivalents AIMT´s has?
What are AIMT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 458
Healthcare Sector # 871
Within the Market # 4184


trailing twelve months Quick Ratio Statistics
High Average Low
39.13 13.73 0.51
(Jun 30 2016)   (Jun 30 2015)




Companies with similar Quick Ratio in the quarter ending Jun 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2020 MRQ Cash & cash equivalentJun 30 2020 MRQ Current Liabilities
Palatin Technologies Inc   21.09 $ 82.852  Millions$ 3.928  Millions
Myokardia Inc   20.87 $ 918.053  Millions$ 43.991  Millions
Iveric Bio Inc   20.79 $ 245.735  Millions$ 11.818  Millions
Crinetics Pharmaceuticals Inc   20.79 $ 205.165  Millions$ 9.870  Millions
Neurogene Inc   20.51 $ 129.596  Millions$ 6.320  Millions
Filana Therapeutics Inc   19.90 $ 25.254  Millions$ 1.269  Millions
Hoth Therapeutics Inc   19.60 $ 6.959  Millions$ 0.355  Millions
Atreca inc   19.52 $ 143.518  Millions$ 7.353  Millions
Trevena inc   19.15 $ 54.795  Millions$ 2.862  Millions
Capricor Therapeutics inc   18.91 $ 36.253  Millions$ 1.918  Millions
Enanta Pharmaceuticals Inc  18.83 $ 370.000  Millions$ 19.650  Millions
Anaptysbio Inc   18.77 $ 377.878  Millions$ 20.130  Millions
Phathom Pharmaceuticals Inc   18.65 $ 247.271  Millions$ 13.258  Millions
Kura Oncology Inc   18.27 $ 338.869  Millions$ 18.551  Millions
Aprea Therapeutics Inc   18.05 $ 112.862  Millions$ 6.252  Millions
Synlogic Inc   18.02 $ 109.136  Millions$ 6.058  Millions
Prothena Corporation Public Limited Company  18.01 $ 333.942  Millions$ 18.544  Millions
Igm Biosciences Inc   17.73 $ 198.090  Millions$ 11.172  Millions
Keros Therapeutics Inc   17.44 $ 144.687  Millions$ 8.294  Millions
Neubase Therapeutics inc   17.39 $ 35.925  Millions$ 2.066  Millions
Uniqure N v   17.27 $ 314.265  Millions$ 18.192  Millions
Milestone Pharmaceuticals Inc   17.12 $ 85.426  Millions$ 4.991  Millions
Larimar Therapeutics Inc   17.11 $ 113.684  Millions$ 6.645  Millions
Dianthus Therapeutics Inc   17.02 $ 176.501  Millions$ 10.369  Millions
Bio Green Med Solution Inc   16.76 $ 25.342  Millions$ 1.512  Millions
Xbiotech Inc   16.25 $ 229.703  Millions$ 14.136  Millions
Revance Therapeutics Inc   15.46 $ 494.043  Millions$ 31.949  Millions
Crescent Biopharma Inc   15.45 $ 149.897  Millions$ 9.701  Millions
Savara Inc   15.44 $ 99.609  Millions$ 6.453  Millions
Seres Therapeutics Inc   15.36 $ 63.940  Millions$ 4.163  Millions

Date modified: 2026-09-12T06:20:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.